Institutional Fund
Frazier Life Sciences Management, L.P.
Palo Alto, CACIK 18921345 filings on record
Portfolio Value
$3.89B
Q1 2026
Holdings
38
Reported positions
New Buys
4
Opened this quarter
QoQ Change
+4.4%
from $3.72B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Mirum Pharmaceuticals Inc18.3%
- Newamsterdam Pharma Company14.0%
- Erasca Inc10.3%
- Bridgebio Pharma Inc6.6%
- Arcutis Biotherapeutics Inc6.0%
- Mbx Biosciences Inc5.1%
- Other39.8%
Portfolio Holdings
38 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Mirum Pharmaceuticals Inc | 7.68M | $709.45M | 18.3% | +884.6K | Added |
| 2 | Newamsterdam Pharma Company | 16.94M | $542.37M | 14.0% | 0 | Held |
| 3 | Erasca Inc | 24.68M | $399.24M | 10.3% | +1.95M | Added |
| 4 | Bridgebio Pharma Inc | 3.45M | $256.06M | 6.6% | −97.4K | Reduced |
| 5 | Arcutis Biotherapeutics Inc | 9.87M | $232.64M | 6.0% | 0 | Held |
| 6 | Mbx Biosciences Inc | 6.65M | $198.56M | 5.1% | 0 | Held |
| 7 | Phathom Pharmaceuticals Inc | 12.47M | $138.50M | 3.6% | 0 | Held |
| 8 | Maze Therapeutics Inc | 4.57M | $136.33M | 3.5% | 0 | Held |
| 9 | Krystal Biotech Inc | 481.3K | $124.33M | 3.2% | −7.2K | Reduced |
| 10 | Trevi Therapeutics Inc | 9.94M | $118.58M | 3.1% | −319.9K | Reduced |
28 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio